Pinned Tweet
$SVRA research in link for free approval play👍🏻⚡️🆙
docs.google.com/document/d/1…
1
1,309
$SVRA 5 days to the PDUFA ⚡️
$4.48 close, $4.35 to $4.60 range today.
52-wk range $4.13 to $7.01. HCW target $10.
Nov 22 is a Sunday, so Friday the 20th is in play.
NFA
1
4
692
$SLS REGAL hit ⚡️
Phase 3 met primary: 41% cut in risk of death, median OS 24 vs 14.7 months, p=0.035.
Opened $24.11, tagged $24.89, closed $19.15 (+156%) on ~120M shares.
After the bell: $150M offering + $22.5M option, $17.10 AH. Data day, then dilution day.
NFA
384
We did not have a position in $CYTK because I did not see much upward movement coming from their approval
2
393
$CYTK got their approval. I had assigned about 90% chance of approval
3
458
$SMMT CRL as we predicted and the reason for it is why we stayed out.
“The CRL indicates that the BLA cannot be approved in its present form, as the FDA determined that substantial evidence of effectiveness is not established in the absence of a statistically significant overall survival (OS) improvement.”
6
813
Last session before Saturday's $SMMT PDUFA ⚡️
$14.23 (-5.6%), was $17.84 three sessions ago. OS HR 0.76, nominal p=0.0151. FDA asked for stat-sig OS.
52-wk low $12.07.
Weekend headline, Monday gap.
NFA
$SMMT 2 days to the PDUFA
FDA told them it wanted stat-sig OS. HARMONi missed it.
September analysis: nominally significant OS in the global population.
CCO seat empty since August.
$15.88, down 4.6% today. 52-wk range $12.07 to $29.23.
Saturday decision = Monday gap either way.
$PEPG priced the $125M raise at $5.00 ⚡️
25M shares + 3.75M option, closes Nov 13.
Priced 4.9% under the $5.26 close. Trading $5.35 premarket, above the deal.
Cash was $104.8M at Sep 30 before this. Last raise was $100M at $3.20 in Sep 2025.
DM1 runway just got a lot longer.
395
$CAPR
Thin evidence: the arm win rests on a single trial with p=0.029. That's significant, but not by a wide margin, and the FDA usually wants either two trials or one very strong one.
Open inspection finding: the July FDA inspection of the clinical trial sites left one finding that Capricor has answered but the FDA hasn't closed. Findings at trial sites go to whether the data can be trusted, so this one matters more than a typical plant-inspection note.
History: there's a prior rejection, and it's a cell therapy, where manufacturing reviews are tough. Narrowing the label in the middle of a review can also read as the company retreating to the claim it can defend.
1
653
Close tape ⚡️
$XBI $156.31 (+0.8%)
$CAPR $11.22 (+26.5%)
$PEPG $5.26 (+14%), $125M offering still unpriced
$COGT $29.40 (-7.1%)
$PYPD $6.60, tagged a new 52-wk high at $7.15
$VTRS $21.06, another 52-wk high
On the clock:
$SMMT $16.64, Sat Nov 14
$SVRA $4.99, Nov 22
$CAPR $11.22, Nov 22
$PYPD $6.60, Nov 28
$COGT $29.40, Nov 30
451
$SMMT 3 days out from the PDUFA and the tape is de-risking
Closed $16.64 (-6.7%), gave back the whole $17.95 premarket.
52-wk range: $12.07 to $29.23.
Fierce: CCO seat empty since August, some launch leaders gone.
Overhang is still the original OS miss.
Decision due Sat Nov 14.
655
